Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
CARM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.38 - $2.66
Previous CloseN/A
Volume72.54K
Average Volume (3M)388.73K
Market Cap
$16.70M
Enterprise Value$17.26M
Total Cash (Recent Filing)$50.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Apr 08, 2025EPS Estimate
-0.16Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding41,750,110
10 Day Avg. Volume158,093
30 Day Avg. Volume388,729
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.82
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.29
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$6.50Price Target Upside1313.04% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Carisma Therapeutics News
PremiumCompany Announcements
Carisma Therapeutics Appoints Interim VP of Finance
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company expects its current cash runway to last through the third quarter of 2025, providing a degree of financial stability.
PartnershipsCarisma's focus is now on partnered programs with Moderna, including a GPC3-targeted program and a liver-fibrosis program, showing potential future growth areas.
Bears Say
Operational ChallengesThe company is undergoing a reorganization with a workforce reduction by 34% and several executives leaving, indicating operational challenges.
Program DiscontinuationCarisma announced the discontinuation of their lead HER-2 monocyte program CT-0525 due to lack of strong enrollment and evolving clinical landscape.
---
Ownership Overview
1.43%
Insiders
4.25% Mutual Funds
3.76% Other Institutional Investors
87.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $0.38 and its highest was $2.66 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Carisma Therapeutics’s market cap is $16.70M.
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is Apr 08, 2025 which is in 26 days.
How were Carisma Therapeutics’s earnings last quarter?
Carisma Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.005.
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Undervalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,750,110 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Carisma Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went down -7.207%.
Which hedge fund is a major shareholder of Carisma Therapeutics?
Currently, no hedge funds are holding shares in CARM
---
Company Description
Carisma Therapeutics
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
---
CARM Stock 12 Month Forecast
Average Price Target
$6.50
▲(1313.04% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Cabaletta Bio
―
Immatics
―
Best Analysts Covering CARM
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-73.48%
reiterated a buy rating 7 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -73.48% per trade.
---